I mostly agree with Dynabolic with the exception t

I mostly agree with Dynabolic with the exception that I believe therapeutics will play much more than a short term role. I respectfully disagree with NotRichYet2's statement regarding Brilacidin as a "good backup". The fact that CV19 continues to mutate makes developing an effective vaccine the equivalent of changing tires on a moving vehicle. I personally believe an effective therapeutic for CV19 will be both the initial and primary weapon against CV19 and future viruses. There will definitely be a push to vaccinate the population but the historical effectiveness of a traditional flu vaccine is 50%-60%. There is also a significant percentage of people adverse to being vaccinated with only 57% of Americans who would take a CV19 vaccine. The challenge of vaccine effectiveness due to complexity and mutation, safety and public willingness to vaccinate, IMO will elevate an effective therapeutic as the primary weapon to combat CV19 and other future pandemics.